# The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)

> **NCT01569438** · PHASE2 · TERMINATED · sponsor: **Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 107 (actual)

## Conditions studied

- Bladder Pain Syndrome

## Interventions

- **DRUG:** Gefapixant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01569438
- **Lead sponsor:** Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04-13
- **Primary completion:** 2014-05-01
- **Final completion:** 2014-05-14
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2020-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569438, "The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01569438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*